Literature DB >> 25336117

A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib.

M Rechsteiner1, P Wild1, M K Kiessling2, A Bohnert1, Q Zhong1, R A Stahel2, H Moch1, A Curioni-Fontecedro3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25336117     DOI： 10.1093/annonc/mdu471

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?

Authors:  P García-Alfonso; J Feliú; R García-Carbonero; C Grávalos; C Guillén-Ponce; J Sastre; J García-Foncillas
Journal:  Clin Transl Oncol       Date:  2016-04-01       Impact factor: 3.405

2.  STAT6 Reliably Distinguishes Solitary Fibrous Tumors from Myofibromas.

Authors:  Molly Housley Smith; Nadim M Islam; Indraneel Bhattacharyya; Donald M Cohen; Sarah G Fitzpatrick
Journal:  Head Neck Pathol       Date:  2017-07-08

Review 3.  Novel therapeutic agents in the treatment of metastatic colorectal cancer.

Authors:  Sachin Gopalkrishna Pai; Jyotsna Fuloria
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

4.  Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.

Authors:  Estelle Daudigeos-Dubus; Ludivine Le Dret; Claudia Lanvers-Kaminsky; Olivia Bawa; Paule Opolon; Albane Vievard; Irène Villa; Mélanie Pagès; Jacques Bosq; Gilles Vassal; Dieter Zopf; Birgit Geoerger
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.